Rigel Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Rigel Pharmaceuticals (South San Francisco, CA): 4 reconciled FDA prescription therapies, $95.1M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | South San Francisco, CA |
| Reconciled FDA Portfolio Therapies | 4 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2032-01-01 |
| 2024 CMS Total Public Spend | $95.1M |
| 2024 Medicare Part D Spend | $77.8M |
| 2024 Medicaid Spend | $17.3M |
| California HCAI SB 17 Filings | 10 WAC filings (max 17.9% 2-yr change) |